WaveMan
WaveMan · Company
ALXO · Alx Oncology Holdings Inc
> Search tickers & screens ⌘K
LIVE
← All companies

ALXO ALX Oncology (ALXO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001810182
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
66
13F, latest reported quarter

What the filings say about ALXO

Insiders, 180 days
-$8.3K net sold
2 sellers · 0% of sales under a 10b5-1 plan

ALX Oncology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ALX ONCOLOGY HOLDINGS INC insiders sold a net $8.3K of stock across 162 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Wong Shelly
SVP, FINANCE AND CAO
SELL
2026-08-18 SECtraded 2026-08-17
573
$1.1K
-45.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 1, 2026.
  • The trade is 0.7% of the 87,828 shares held after it.
  • 1 other insider sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, FINANCE AND CAO Wong Shelly sold about $1.1K of ALXO on Aug 17, 2026; 1 other insider sold within 30 days and 66 funds added in the latest 13F quarter.
Lettmann Jason
CHIEF EXECUTIVE OFFICER
SELL
2026-08-18 SECtraded 2026-08-17
2,230
$4.3K
-45.1%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (3 buys, 19 sales), the last on Mar 19, 2026.
  • +29.6% median (+14.1% mean) 90-day return after 3 previous buys.
  • The trade is 0.8% of the 294,379 shares held after it.
  • 1 other insider sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Lettmann Jason sold about $4.3K of ALXO on Aug 17, 2026; 1 other insider sold within 30 days and 66 funds added in the latest 13F quarter.
Wong Shelly
SVP, FINANCE AND CAO
SELL
2026-07-06 SECtraded 2026-07-01
1,404
$2.9K
-52.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.6% of the 88,401 shares held after it.
  • No other insider sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, FINANCE AND CAO Wong Shelly sold about $2.9K of ALXO on Jul 1, 2026; 66 funds added in the latest 13F quarter.
Lettmann Jason
CHIEF EXECUTIVE OFFICER
SELL
2026-03-23 SECtraded 2026-03-19
12,311
$26.7K
-44.6%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (3 buys, 18 sales), the last on Sep 17, 2025.
  • +29.6% median (+14.1% mean) 90-day return after 3 previous buys.
  • The trade is 4.2% of the 293,609 shares held after it.
  • 1 other insider sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Lettmann Jason sold about $26.7K of ALXO on Mar 19, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 66 funds added in the latest 13F quarter.
Pinto Shelly
SVP, FINANCE AND CAO
SELL
2026-03-23 SECtraded 2026-03-19
903
$2.0K
-44.6%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Feb 18, 2026.
  • The trade is 1.0% of the 86,805 shares held after it.
  • 1 other insider sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, FINANCE AND CAO Pinto Shelly sold about $2.0K of ALXO on Mar 19, 2026; 1 other insider sold within 30 days and 66 funds added in the latest 13F quarter.
162 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 157 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$8.3K over 180 days
-$5.4K over 90 days
more than 61% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
66 funds bought in last quarter
more than 54% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.0% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
below 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ALXO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-29.8%12M
-44%-9%+26%+61%2025-102025-122026-022026-042026-062026-082026-10 2026-02-02 · GOODMAN COREY S bought $5.0M2026-03-19 · Lettmann Jason sold $26.7K2026-01-06 · Pinto Shelly sold $4.4K2026-08-17 · Lettmann Jason sold $4.3K2026-07-01 · Wong Shelly sold $2.9K2026-03-19 · Pinto Shelly sold $2.0K2026-02-18 · Pinto Shelly sold $1.3K2026-08-17 · Wong Shelly sold $1.1K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ALXO: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
13,011,849 sh
$26.9M
venBio Partners LLC
12,884,638 sh
$26.7M
BlackRock, Inc.
7,399,530 sh
$15.3M
Redmile Group, LLC
7,392,504 sh
$15.3M
Blackstone Inc.
6,593,543 sh
$13.6M

Congress trades in ALXO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ALXO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ALXO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$436.8K position · as of 2026-06-30
0.3%
LVIP JPMorgan Small Cap Core Fund
$181.7K position · as of 2026-06-30
0.1%
JPMorgan U.S. Small Company Fund
$815.5K position · as of 2026-06-30
0.1%
Goldman Sachs Small Cap Growth Insights Fund
$162.9K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$748.9K position · as of 2026-06-30
0.0%
VY(R) JPMORGAN SMALL CAP CORE EQUITY PORTFOLIO
$119.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $8.3K sold by insiders over 180 days, 66 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ALXO financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2M
four quarters, 2020-01-01 to 2020-12-31
Net margin, TTM
-6,843%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$71.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.07x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-7.29x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-80.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-63.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-74.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$143.3M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-45.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$0
Operating income-$104.0M-$142.5M-$170.3M-$127.4M
Net income-$101.7M-$134.8M-$160.8M-$123.5M
EPS (diluted)-1.90-2.58-3.74-3.03
Operating cash flow-$84.1M-$121.9M-$130.4M-$89.2M
Cash$16.4M$17.6M$22.4M$48.8M
Long-term debt$4.5M$9.5M$9.6M$9.4M
SEC XBRL, fiscal years, as known on 2026-10-27

ALXO Stock Sonar score 5/7 axes

Find similar shapesCompare

ALXO ranks highest on risk and compliance (67th percentile) and institutional and government (54th), and lowest on insider conviction (30th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
37
Inputs
  • Return on equity-80.6% · 38 pct, sector of 545
  • Return on assets-63.2% · 37 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-74.2% · 35 pct, sector of 576
Financial health
42
Inputs
  • Debt to equity0.07x · 59 pct, sector of 352
  • Cash flow to debt-7.29x · 26 pct, sector of 371
Insider conviction
30
Inputs
  • Net Form 4 buying (codes P and S), 180d-$8K · 60 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
54
Inputs
  • Funds adding, latest quarter66 · 54 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
67
Inputs
  • Short interest, % of float+6.0% · 54 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.7% · 80 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ALXO filings, in plain words

Are ALX Oncology insiders buying or selling ALXO?

In the 180 days to 2026-10-27, ALX Oncology insiders were net sellers, a net $8.3K across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-27, ALX Oncology insiders were net sellers of ALXO, a net $8.3K across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies